Search Results

10 results for cancer

Trends in Tier 1 Genomic Applications 2013-2022

two figures looking at genomics trends with the text Tier 1 Applications

The CDC Tier 1 genomic applications database can help consumers, providers, health care organizations and public health programs accelerate the translation of genomic discoveries into improved population health.       Background Advances in genomics and precision medicine are proceeding at a rapid pace. Many genomic tests have reached clinical practice without clear indication as to whether their

Posted on by Mindy Clyne, W. David Dotson, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags ,

Genomics, Health Equity, and Global Health

two hands holding the world surrounding by DNA and a crowd

The World Health Organization’s Science Council recently issued its first report on accelerating access to genomics for global health. The report makes a strong case for less-resourced countries to gain access to such technologies. Although remarkable progress has been made in the translation of genomic discoveries into health benefits, in 2020, the World Health Organization (WHO) reminded

Posted on by Jeffery Osei, Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; George Mensah, Center for Translation Research and Implementation Science, National Heart, Lung, Blood Institute, Bethesda, Maryland; Muin J. Khoury, Office of Genomics and Precision Public Health, Atlanta, GeorgiaTags ,

Polygenic Risk Scores in Clinical Practice? Still Making the Case

a polygenic risk score curve with a double helix, a doctor pointing at a tablet with icons surround it, and a doctor talking to her patient

Two recent systematic reviews show the lack of data on clinical utility of polygenic risk scores and major challenges in implementation. The Promise of Polygenic Risk Scores in Population Health Many common diseases such as cancer, diabetes, and heart disease, result from the combination of genetic factors and physical and social environmental factors. Genome-wide association

Posted on by Jeffery Osei, Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; W. David Dotson, Marta Gwinn, Ridgely Fisk Green, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta GeorgiaTags , ,

Population Genomic Screening is Here: We Need Evidence on Health Impact and Optimal Implementation

a population with a double helix and genetic testing

A recent study identified 12 population-based genomic screening programs in the United States and described their implementation logistics and potential health impact. In the past decade, the promise of genomic screening in the general population has garnered increasing interest due to a combination of factors such as enhanced sequencing capabilities, lowered costs of testing, and

Posted on by Muin J. Khoury and W. David Dotson, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia2 Comments

Tracking the Scientific Literature on the Impact of Pharmacogenomics on Clinical Practice and Public Health

bar graph of Trends in pharmacogenomic implementation studies, 2012-2021

Pharmacogenomics (PGx) is an emerging field that investigates genetic differences in drug effectiveness and safety. PGx is an essential component of precision medicine  and seeks to provide the right medication for the right person at the right time. Advances in PGx promise to improve treatment of many diseases such as cancer and cardiovascular disease. In

Posted on by Sarina Abrishamcar, Emory University Rollins School of Public Health, W. David Dotson, and Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention

Epigenetics: An Emerging Tool for Health Equity Science

people holding hands below DNA

A recent review provides recommendations to improve the scientific investigation of the associations between epigenetic markers, socioeconomic status, and adverse health outcomes. Health equity means that everyone has the opportunity to be as healthy as possible. Health equity science studies the association between social determinants of health (SDOH) and adverse health outcomes. SDOH refer to

Posted on by Emily Drzymalla, Marta Gwinn, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and PreventionTags

Artificial Intelligence in Medicine and Public Health: Prospects and Challenges Beyond the Pandemic

a woman pointing at DNA wiith AI in the background

Though still in its infancy as a field, artificial intelligence (AI) is poised to transform the practice of medicine and the delivery of healthcare. Powered by breakthroughs in machine learning (ML) algorithms, enhanced computing power, and increasing data volume and storage capacity, AI has made noteworthy advances over the past decade across many medical subspecialties.

Posted on by Danielle Rasooly, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags

Equitable Implementation of Cascade Testing for Genetic Disorders: Where are We?

a cascade testing pedigree with a scale and a figure with a magnifying glass looking at a question mark

Testing relatives of individuals with genetic disorders, a process known as cascade testing or cascade screening, is critical for identifying those needing health services that can prevent morbidity and mortality. Yet, cascade testing is poorly implemented in clinical practice. For example, there are several genetic conditions with CDC tier 1 evidence-based recommendations for cascade testing,

Posted on by Mindy Clyne, W. David Dotson, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaTags , ,

From Precision Medicine to Precision Public Health: The Dialogue Continues

Precision on a triangle above Medicine and Public Health with the map of the US in the middle filled with a population and DNA and a magnifying glass on a person in red

A recent Nature article discusses the concept of precision public health (PPH) and raises concerns that too much emphasis on data and technology is “diverting attention away from regular public health.” In this post, we advance this important dialogue by focusing on two distinct components of PPH: its role in reaping the population health benefits

Posted on by Muin J. Khoury, Office of Genomics and Precision Public Health, Atlanta, Georgia, and Josh Denny, All of Us Research Program, National Institutes for Health, Bethesda, MarylandTags

The Current Landscape of CDC Publications in Human Genomics and Public Health

sequencing with a double helix and a doctor pointing to different icons above a farm field

In October 2021, the CDC Office of Genomics and Precision Public Health (OGPPH) launched a new, five-year initiative to strengthen public health capacity in genomics and precision medicine. The emergence of evidence-based genomic applications and lack of equity in their implementation in clinical and public health practice provided an important impetus for this initiative. To

Posted on by Mindy Clyne, W. David Dotson, Anja Wulf, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia